Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review

Introduction

Multiple myeloma (MM) is the second most common hematological cancer, and results from the accumulation of malignant plasma cells in the bone marrow (1). MM is responsible for ~1% of all cancers and 10% of hematological cancers (1,2). The median age at diagnosis of MM is 70 years (3). MM is associated with a number of complications, which include: Hematological complications, such as anemia, bone marrow failure and bleeding disorders; bone complications, such as pathological fractures and lytic bone lesions; renal insufficiencies; compromised immune function; and neurological complications, such as spinal cord and nerve root compression and cranial nerve compression, which are often associated with base of skull lesions (1). The median survival of patients with MM was <1 year prior to the introduction of alkylating agents (4). The introduction of novel agents, including bortezomib, thalidomide and lenalidomide, for the treatment of MM patients has significantly improved clinical outcomes (3,5).

Bortezomib is a proteasome inhibitor that exhibits significant anti-myeloma activity. The majority of adverse effects associated with bortezomib are mild or moderate and are generally manageable, including gastrointestinal symptoms, peripheral neuropathy and thrombocytopenia (6). Severe pulmonary complications have rarely been reported. The present study reports the case of a patient in whom life-threatening pulmonary adverse effects developed after receiving bortezomib combined with thalidomide and dexamethasone for newly diagnosed MM.

Case report

A 62-year-old man was referred to The Second Affiliated Hospital, Zhejiang University College of Medicine (Hangzhou, Zhejiang, China) due to dizziness and weakness that had been apparent for 3 months, since August 2013. The patient had a 9-year history of coronary heart disease, for which the standard medications (aspirin, 100 mg/day; atorvastatin, 20 mg/day; metoprolol, 25 mg/day; all for 9 years) were administered, and a >30-year history of smoking, which the patient quitted after being diagnosed with coronary heart disease. There was no history of respiratory diseases. At the cardiological clinic in The Second Affiliated Hospital, Zhejiang University College of Medicine, the patient was found to have moderate anemia. Furthermore, serological tests and bone marrow studies confirmed the pathologic diagnosis of MM [IgG type; Durie-Salmon, stage III (7)]. The patient was consequently admitted for chemotherapy.

Treatment with bortezomib (1 mg/m2 on days 1, 4, 8 and 11), thalidomide (100 mg/day) and dexamethasone (20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12) was employed in a 21-day cycle. The initial chest high-resolution computed tomography (HRCT) scan was normal. The first cycle was effective and uneventful. However, on the eve of the second cycle, the patient developed a moderate fever (38.5°C) and a mild dry cough. Despite the fact that the leukocyte count and lung auscultation were normal, moxifloxacin (400 mg/day) was prescribed to prevent probable pneumonia. The fifth and sixth agents of bortezomib were administered on schedule. After the sixth agent, the patient's temperature ascended to 39.1°C, and auscultation revealed crackles in the left lung. The chest HRCT scan demonstrated a newly developed consolidation in the upper lobe and infiltration in the lower lobe of the left lung (Fig. 1). Pneumonia was initially considered due to the immunosuppressive status of the patient, and intravenous broad-spectrum antibiotics (including 500 mg imipenem/cilastatin every 8 h, 1,000 mg vancomycin every 12 h and 200 mg voriconazole every 12 h) were administered.

Figure 1. Chest high-resolution computed tomography scan on the day of the sixth dose of bortezomib showing newly developed consolidation and infiltration in the left lung.

However, the patient's clinical condition worsened following the treatment. The next day, asthma-like symptoms and mild dyspnea were noted, and the patient began to expectorate bloody sputum. The high fever remained (maximum temperature, 39°C). Acute respiratory distress (SpO2, 85%) on room air developed 3 days later. The chest HRCT scan showed bilateral diffuse alveolar infiltrations, multiple subpleural lesions and slight pleural effusion (Fig. 2). The chemotherapy was discontinued due to the patient's poor clinical condition. Infection by virus and/or Pneumocystis jiroveci could not be definitively excluded; therefore, ganciclovir (300 mg every 12 h for 3 days) and trimethoprim/sulfamethoxazole (960 mg every 12 h for 3 days) were added into the therapy. Intravenous immunoglobulin (10 g/day for 6 days; then 5 g/day for 3 days) was also administered to strengthen the patient's immunity. The patient was then transferred into the Intensive Care Unit.

Figure 2. Chest high-resolution computed tomography scan 3 days after the sixth dose of bortezomib showing rapidly deteriorating lung injury with bilateral diffuse alveolar infiltration and multiple subpleural lesions.

Despite receiving a large number of powerful antibiotics, the patient's clinical status did not improve. The patient retained an SpO2 level of 92% when masked with a reservoir bag, and a flow rate of 15 l/min oxygen. Serological tests, including repeated C-reactive protein (CRP) and procalcitonin (PCT) analysis, were normal. The bacteriological and mycological cultures of the sputum and blood samples were negative. No invasive investigations, such as bronchoalveolar lavage or transbronchial biopsy, were performed due to thrombocytopenia and the critical condition of the patient. A suspected diagnosis of a bortezomib-induced severe pulmonary complication was formed, and 120 mg/day methylprednisolone was instigated. The respiratory failure was relieved 5 days later and a normal temperature was recorded. The dose of methylprednisolone was tapered (120 mg/day for 2 days; 80 mg/day for 2 days; 40 mg/day for 2 days; 30 mg/day for 2 days; 20 mg/day for 2 days; then discontinued), the patient's clinical condition improved gradually and the results on chest HRCT scan improved synchronously (Fig. 3). Another 18 days later, the patient was discharged without any respiratory symptoms.

Figure 3. Chest high-resolution computed tomography scan 12 days after starting corticosteroid treatment showing marked improvement of the lung infiltration.

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Discussion

The first study of MM patients who developed life-threatening pulmonary complications after receiving bortezomib therapy reported the cases of 4 Japanese patients (6). Since this time, 16 cases have been described as MM with bortezomib-induced pulmonary complications (6,8–15). The patient in the present study also developed severe pulmonary complications during bortezomib treatment. The differential diagnosis included infectious pneumonia and drug-induced pulmonary toxicity. The clinical course in this case was similar to those previously reported cases. The patient developed symptoms that included a fever, a cough, bloody sputum, gradual dyspnea, and ultimately, respiratory failure. The chest HRCT scan showed diffuse infiltration and consolidation of the bilateral lungs, accompanied with slight pleural effusion. The inflammatory markers, CRP and PCT, were normal. All the cultures of the blood and sputum were negative. Powerful broad-spectrum antibiotics were inefficacious. Therefore, the patient was diagnosed with bortezomib-induced severe pulmonary complications. Although no histopathological evaluation was obtained to prove the diagnosis, a good response to corticosteroids favored the diagnosis, as observed in previous reports (9,12,15).

The clinical characteristics of all 16 reported patients are listed in Table I. The cases consisted of 10 male patients (62.5%) and 6 female patients (37.5%). The mean age was 62.3 years (range, 47–74 years). Only 3 patients (18.8%) had a previous history of respiratory diseases [including invasive pulmonary aspergillosis (6), pulmonary embolism (6) and chronic obstructive pulmonary disease (9)], while 11 (68.8%) had not, and 2 had an unknown history. In total, 9 patients (56.3%) were of IgG type, 2 (12.5%) of IgD type, 1 (6.3%) of IgA type, 1 (6.3%) of IgC type and 3 (18.8%) of unknown type. The cases consisted of 10 relapsed patients (62.5%), 4 newly diagnosed patients (25%) and 2 refractory patients (12.5%). A total of 6 patients (37.5%) had received autologous peripheral blood stem cell transplantation (auto-PBSCT) prior to treatment with bortezomib, 1 (6.3%) had received an unrelated bone marrow transplantation, 4 (25%) had no transplantation history and 5 (31.3%) had an unknown transplantation history. Therefore, the male gender, IgG type, relapse state and previous history of auto-PBSCT may be risk factors for bortezomib-induced severe pulmonary complications in MM.

Table I. Characteristics of 16 MM patients with bortezomib-induced severe pulmonary complications.

Table I.

Characteristics of 16 MM patients with bortezomib-induced severe pulmonary complications.

First author, year	Age, years	Gender	MM type	Previous history of lung injury	Status of MM prior to bortezomib therapy	Prior transplantation	Ref.
Miyakoshi et al, 2006	47	F	IgG	Invasive pulmonary aspergillosis	Relapse	Auto-PBSCT	(6)
	59	F	IgA	Pulmonary embolism	Relapse	Auto-PBSCT
	48	F	IgD	No	Relapse	Unrelated bone marrow transplantation
	53	F	Unknown	No	Relapse	Auto-PBSCT
Boyer et al, 2006	66	M	Unknown	No	Relapse	No	(8)
Zappasodi et al, 2007	66	M	Unknown	COPD	Refractory	Unknown	(9)
Dun et al, 2010	72	M	IgG	No	Relapse	Unknown	(10)
	51	M	IgD	No	Refractory	Unknown
	72	F	IgG	No	New	No
	68	F	IgG	No	Relapse	Unknown
	72	M	IgG	No	Relapse	Unknown
Kang et al, 2010	67	M	IgG	Unknown	New	No	(11)
Yamaguchi et al, 2012	64	M	IgG	No	Relapse	Auto-PBSCT	(12)
Vandeix et al, 2012	74	M	IgC	No	New	No	(13)
Chew et al, 2007	66	M	IgG	Unknown	New	Auto-PBSCT	(14)
Pitini et al, 2007	51	M	IgG	No	Relapse	Auto-PBSCT	(15)

[i] Ig, immunoglobulin; COPD, chronic obstructive pulmonary disease; auto-PBSCT, autologous peripheral blood stem cell transplantation; M, male; F, female; MM, multiple myeloma.

In the 16 cases, the mean number of bortezomib injections administered prior to severe pulmonary complications appearing was 6.9 (range, 1–32), and the mean time from the first administration of bortezomib to the appearance of severe pulmonary complications was 31.3 days (range, 1–161 days) (Table II).

Table II. Clinical details, treatments and outcomes of 16 multiple myeloma patients with bortezomib-induced severe pulmonary complications.

Table II.

Clinical details, treatments and outcomes of 16 multiple myeloma patients with bortezomib-induced severe pulmonary complications.

First author, year	Bortezomib doses prior to symptoms	Time after first bortezomib administration, days	Combined with corticosteroid	Clinical manifestations	Chest radiological findings	Pathological findings	Initial corticosteroid type and dose	Outcome	Ref.
Miyakoshi et al, 2006	8	35	No	Cough, asthma-like symptoms, fever, dyspnea, respiratory failure	Bilateral infiltrates	Organizing diffuse alveolar damage	Methylprednisolone, 1,000 mg	Mortality	(6)
	4	18	No	Dyspnea, fever, asthma-like symptoms, respiratory failure	Right pleural effusion and pulmonary edema	No	Methylprednisolone, 1,000 mg	Alive
	4	11	No	High-grade fever, respiratory failure	Bilateral infiltrates with pleural effusions	No	Methylprednisolone, 500 mg	Alive
	1	1	No	Dyspnea, wheezing, low-grade fever, respiratory failure	Bilateral infiltrates	No	Methylprednisolone, 1,000 mg	Mortality
Boyer et al, 2006	9	43	No	Cough, dyspnea, fever, acute respiratory failure	Bilateral infiltrates and consolidations	Fibrosis with admixed chronic inflammatory cells	Prednisone, 60 mg	Alive	(8)
Zappasodi	8	42	Yes	Respiratory failure	Bilateral consolidations ground glass opacities, bilateral pleural effusion	No	Methylprednisolone, 500 mg	Alive	(9)
Dun et al, 2010	7	29	Yes	Fever, cough, pursiness, dyspnea, respiratory failure	Bilateral pleural effusion, pulmonary infiltrates	No	Methylprednisolone, 160–640 mg	Mortality	(10)
	2	5	Yes	Breath lessness, fever, dyspnea, respiratory failure	Pulmonary infiltrates, ground glass opacities	No	Methylprednisolone, 160–640 mg	Mortality
	3	8	Yes	Dyspnea	Left pleural effusion, pulmonary edema	No	Methylprednisolone, 160–640 mg	Mortality
	2	4	Yes	Breath lessness, fever, dyspnea, respiratory failure	Pulmonary edema	No	Methylprednisolone, 160–640 mg	Mortality
	8	32	Yes	High fever, acute respiratory failure	Pulmonary edema	No	Methylprednisolone, 160–640 mg	Mortality
Kang et al, 2010	4	21	Yes	Dyspnea	Ground glass appearance	Diffuse interstitial fibrosis	Unknown	Alive	(11)
Yamaguchi et al, 2012	2	13	Yes	Dry cough, fever, dyspnea	Bilateral ground glass, opacities peripheral	No	Prednisolone, 1 mg/kg	Alive	(12)
Vandeix et al, 2012	32	161	Yes	Cough, dyspnea, acute respiratory distress	Bilateral interstitial alveolar infiltration, right pleural effusion	Bronchiolitis obliterans with organizing fibroblastic polyps in alveoli	Methylprednisolone, 1 mg/kg	Alive	(13)
Chew et al, 2007	8	35	Yes	Severe dyspnea, respiratory failure	Extensive bilateral acute pulmonary injury	No	Methylprednisolone, dose unknown	Mortality	(14)
Pitini et al, 2007	9	43	Unknown	Dyspnea, acute respiratory failure	Bilateral multiple pulmonary infiltrates	No	Methylprednisolone, 1,000 mg	Alive	(15)

The most common clinical symptoms of bortezomib-induced severe pulmonary complications were dyspnea (13/16; 81.3%), respiratory failure (13/16; 81.3%), a fever (10/16; 62.5%) and a cough (5/16; 31.3%). The most common radiological findings were pulmonary infiltration (9/16; 56.3%), pleural effusion (6/16; 37.5%), pulmonary edema (4/16; 25%) and ground-glass opacities (4/16; 25%) (Table II).

Due to the poor clinical condition of the patients, only 4 (25%) achieved a pathological diagnosis [organizing diffuse alveolar damage (6), fibrosis with admixed chronic inflammatory cells (8), diffuse interstitial fibrosis (11) and bronchiolitis obliterans with organizing fibroblastic polyps in alveoli (13), respectively] that totally accounted for the changes of the pulmonary interstitium. The inner mechanism of bortezomib-induced severe pulmonary complications remains unclear. However, the following pathogenetics have been involved in the development of lung injury: i) Activation nuclear factor-κB-related proinflammatory factors, including tumor necrosis factor-α, interleukin (IL)-6, IL-1β and IL-11; and ii) accumulation of bortezomib and/or its metabolites, altering multiple signaling pathways (6,10,13).

All patients received corticosteroid therapy following the occurrence of severe pulmonary complications, however, while half of these patients experienced improvement, the other half succumbed. Among the 7 patients in whom corticosteroid types or doses were not precisely mentioned, 6 patients (85.7%) succumbed and 1 patient (14.3%) improved (Table II).

The first hypothesis of proinflammatory factors would explain the good response to corticosteroid therapy in certain patients (9,13); however, other patients developed severe pulmonary complications even when receiving dexamethasone in combination with bortezomib. In all 16 reported patients, 10 (62.5%) were administered corticosteroids concurrently with bortezomib, while 5 (31.3%) were not and in 1 case this was unknown. Among the 10 cases that received bortezomib combined with corticosteroids, 4 (40%) showed improvement and 6 (60%) succumbed when retreated with corticosteroids. However, among the 5 cases that received bortezomib without corticosteroids, 3 (60%) showed improvement and 2 (40%) succumbed. Despite the fact that retreatment with corticosteroids remained efficacious, it appeared that outcomes of patients who received corticosteroids combined with bortezomib were worse than those treated with bortezomib only. This would suggest the existence of another unknown complex pathogenesis. Further investigations are required to elucidate the underlying reasons.

In a number of the early published studies (6,9,15), the patients mainly received high-dose corticosteroids (500–1,000 mg/day methylprednisolone), but the outcomes were not totally satisfactory. Among the 6 patients who received high-dose corticosteroids, 4 (66.7%) showed improvement and 2 (33.3%) succumbed. However, low-dose corticosteroids (1 mg/kg/day methylprednisolone/prednisolone) showed a good response in several cases (8,12,13). All 3 of the patients who received low-dose steroids showed improvement. In the present case, success was also achieved with 120 mg methylprednisolone initially.

In two particular cases reported by Miyakoshi et al (6) and Chew et al (14), the patients experienced two episodes of drug-induced pulmonary adverse effects in their whole course of bortezomib therapy. The first pulmonary complications improved spontaneously or through treatment with corticosteroid. However, severe pulmonary complications developed again and the patients ultimately succumbed when retreated with bortezomib. As a result, we hypothesize that retreating patients with bortezomib after a ‘sentinel’ episode of lung injury, a history of pulmonary complications during the previous treatment with bortezomib, could be fatal and should be avoided.

In conclusion, clinicians should be aware of potential severe pulmonary complications in patients receiving bortezomib, even when combined with dexamethasone, and particularly in patients who are male, of IgG type, with a relapse status and a history of auto-PBSCT. In the literature review, it was noted that when severe pulmonary complications were present, corticosteroids remained the only effective drug. It appears that the outcomes of the patients who received corticosteroids combined with bortezomib were worse than those for patients treated with bortezomib only. Considering the adverse effects associated with high-dose corticosteroids, a relatively low dose could be more suitable. At the same time, bortezomib should be discontinued immediately. Retreating patients with bortezomib after a ‘sentinel’ episode of lung injury could be fatal and should be avoided.

Acknowledgements

The authors would like to thank Dr Lili Yang and Dr Rongwang Yang (The Children's Hospital, Zhejiang University College of Medicine) for copy-editing the original manuscript.

Glossary

Abbreviations

Abbreviations:

References